What's in Chengdu Kanghong Biotech Co., Ltd.'s pipeline?

Chengdu Kanghong Biotech Co., Ltd. has 6 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Chengdu Kanghong Biotech Co., Ltd.'s portfolio?

Top competitors by shared drug class: Air Force Military Medical University, China, Akeso, Biotech Pharmaceutical Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Central European Society for Anticancer Drug Research.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chengdu-kanghong-biotech-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Chengdu Kanghong Biotech Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chengdu Kanghong Biotech Co., Ltd. pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
conbercept, Fixed	conbercept, Fixed	phase 3	VEGF decoy receptor	VEGF	Ophthalmology
Conbercept ophthalmic injection	Conbercept ophthalmic injection	phase 3	VEGF/PlGF inhibitor; recombinant fusion protein	VEGF (vascular endothelial growth factor); PlGF (placental growth factor)	Ophthalmology
conbercept, PRN	conbercept, PRN	phase 3	VEGF/PlGF inhibitor (recombinant fusion protein)	VEGF (vascular endothelial growth factor) and PlGF (placental growth factor)	Ophthalmology
Placebo + Paclitaxel	Placebo + Paclitaxel	phase 3	Taxane	Microtubules	Oncology

Therapeutic area mix

Ophthalmology · 4
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Air Force Military Medical University, China · 1 shared drug class
Akeso · 1 shared drug class
Biotech Pharmaceutical Co., Ltd. · 1 shared drug class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
Central European Society for Anticancer Drug Research · 1 shared drug class
Fourth Affiliated Hospital of Guangxi Medical University · 1 shared drug class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 shared drug class
AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chengdu Kanghong Biotech Co., Ltd.:

Cite this brief

Drug Landscape (2026). Chengdu Kanghong Biotech Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chengdu-kanghong-biotech-co-ltd. Accessed 2026-05-17.